In heart failure, all beta-blockers are not necessarily equal

W.H. Wilson Tang, MD
The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic

Michael Militello, PharmD
Department of Pharmacy, The Cleveland Clinic

Gary S. Francis, MD
Director, Coronary Intensive Care Unit, The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: W.H. Wilson Tang, MD, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F25, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: tangw@ccf.org

Dr. Francis has indicated that he is on the advisory board of GlaxoSmithKline.

W.H. Wilson Tang, MD
The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic

Michael Militello, PharmD
Department of Pharmacy, The Cleveland Clinic

Gary S. Francis, MD
Director, Coronary Intensive Care Unit, The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: W.H. Wilson Tang, MD, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F25, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: tangw@ccf.org

Dr. Francis has indicated that he is on the advisory board of GlaxoSmithKline.

W.H. Wilson Tang, MD
The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic

Michael Militello, PharmD
Department of Pharmacy, The Cleveland Clinic

Gary S. Francis, MD
Director, Coronary Intensive Care Unit, The George M. and Linda H. Kaufman Center for Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic

Address: W.H. Wilson Tang, MD, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, F25, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: tangw@ccf.org

Dr. Francis has indicated that he is on the advisory board of GlaxoSmithKline.